Notice ID: c1d10d38341949b68668012ec7bf8bb6Combined Synopsis/Solicitation
Acquisition of cGMP-grade GS-441524 for the Treatment of COVID-19
Archived on December 7, 2020. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 8:59 AM UTC−05:00
- Posted
- November 24, 2020
- Notice type
- Combined Synopsis/Solicitation
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH NIDA
- Last updated
- Sep 25, 2026
Identifiers
- Solicitation number
- 75N95021Q00015
- Notice ID
- c1d10d38341949b68668012ec7bf8bb6
Description
The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), with a mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. NCATS is evaluating GS-441524 as a potential treatment for SARS-CoV-2 infection. GS-441524 is the parent nucleoside of remdesivir and has similar efficacy to remdesivir in vitro. GS-441524 is a stable crystalline compound with good physical properties for formulation, and the 3-step synthesis of GS-441524 makes it suitable for large scale production. The purpose of this acquisition is to provide Chemistry, Manufacturing and Controls (CMC) support for the preclinical and clinical development of GS-441524 as a potential antiviral against SARS-CoV-2, the causative agent of the pandemic disease COVID-19. NCATS will perform preclinical and Phase 1 clinical studies with GS-441524, and gather information on its safety and tolerability, efficacy, pharmacokinetics, and dose-range in human. To cover the requirements of the studies, NCATS will need a batch of GS-441524 adhering to current Good Manufacturing Practice (cGMP) guidelines from a qualified Contract Manufacturing Organization (CMO). See attached Request for Quotations and associated attachments for complete requirement details.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
No documents available.
Lifecycle
Solicitation:
75N95021Q00015- Combined Synopsis
- Combined SynopsisCurrentNov 24, 2020
Acquisition of cGMP-grade GS-441524 for the Treatment of COVID-19
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
75N95021Q00015
Archive Date
Dec 7, 2020
Office Address
Bethesda, MD, 20892